<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080336</url>
  </required_header>
  <id_info>
    <org_study_id>dinoprostone misoprostol IUD</org_study_id>
    <nct_id>NCT04080336</nct_id>
  </id_info>
  <brief_title>Comparison of Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Nulliparous Women</brief_title>
  <official_title>Comparison of Vaginal Misoprostol and Dinoprostone Prior to Copper Intrauterine Device Insertion in Nulliparous Women:a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of vaginal dinoprostone versus vaginal misoprostol administered before
      the copper intrauterine device(IUD) insertion in reducing IUD inertion pain and the
      difficulty in inserting the IUD in nulliparous women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-acting reversible contraception methods are highly effective methods for reduction of
      the unplanned pregnancy rate worldwide. The intrauterine device is a single procedure that
      provides reliable, effective and long term contraception for many women. However, the
      insertion procedure can be associated with a troublesome degree of pain that prevent some
      women from choosing its use. Different interventions have been described to decrease pain
      perception during intrauterine device insertion with no agreement on an effective one.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in pain scores during intrauterine device insertion</measure>
    <time_frame>10 minutes</time_frame>
    <description>The difference in pain scores during intrauterine device insertion using visual analog scale from 0 to 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the difference in pain scores during tenaculum application</measure>
    <time_frame>10 minutes</time_frame>
    <description>The difference in pain scores during tenaculum application using a visual analog scale from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the difference in pain scores during sound insertion</measure>
    <time_frame>10 minutes</time_frame>
    <description>The difference in pain scores during sound insertion using a visual analog scale from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the ease of IUD insertion</measure>
    <time_frame>10 minutes</time_frame>
    <description>the ease of IUD insertion using ease of insertion score from 0 to 10 cm (0 = very easy insertion, 10 cm = terribly difficult insertion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>women's satisfaction level</measure>
    <time_frame>10 minutes</time_frame>
    <description>women's satisfaction level using satisfaction score from 0 to 10 cm where 0 denotes no satisfaction and 10 denotes maximum satisfaction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>IUD Insertion Complication</condition>
  <arm_group>
    <arm_group_label>dinoprostone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin速 E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 vaginal tablet of misoprostol (200 mcg) (Misotac速; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone</intervention_name>
    <description>1 vaginal tablet of dinoprostone (3mg) (prostin速 E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.</description>
    <arm_group_label>dinoprostone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>1 vaginal tablet of misoprostol (200mcg) (Misotac速; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.</description>
    <arm_group_label>misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nulliparous women requesting copper IUD insertion

        Exclusion Criteria:

          -  pregnancy, Parous women, contraindications or allergy to dinoprostone or
             misoprostol,contraindication to IUD insertion, untreated active cervicitis or
             vaginitis, undiagnosed abnormal uterine bleeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED SAMY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed El Sharkawy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed El Mahy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ahmed Samy</name>
      <address>
        <city>Giza</city>
        <zip>11231</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

